PO.IM01.07 · 免疫学

人gammadelta T细胞在人源化NSG™-SGM3-IL-15×MHC I/II双敲除小鼠中的稳健植入,用于评估基于gammadelta T细胞的治疗手段

Robust engraftment of human gammadelta T cells in humanized NSG TM -SGM3-IL-15 × MHC I/II double knockout mice for the evaluation of gammadelta T cell-based therapeutics

海报缩略图:人gammadelta T细胞在人源化NSG™-SGM3-IL-15×MHC I/II双敲除小鼠中的稳健植入,用于评估基于gammadelta T细胞的治疗手段
编号 154 展板 28 时间 4/19 02:00–05:00 区域 Section 7 主讲 Kevin Tsai, PhD
分会场 Alternative Cell Type and in Situ Cell Therapies
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Kevin Tsai, Beau Parry, Destanie Rose, James G. Keck, Li-Chin Yao

Innovation and Product Development, The Jackson Laboratory, Sacramento, CA

摘要 Abstract

中文摘要
背景:Gamma delta(gammadelta)T细胞是T淋巴细胞的一个次要亚群,能够识别癌细胞表达的一系列广泛保守的抗原。与传统T细胞不同,其识别不依赖MHC,使其成为针对各类恶性肿瘤的下一代通用癌症疗法的有力候选。我们的初步供者筛选结果表明,将人外周血单个核细胞(PBMC)植入经辐照的NSG™-SGM3-IL-15×MHC I/II DKO(SDKO)小鼠,可使循环gammadelta T细胞扩增至与人体相当的浓度,并可从组织中稳健回收gammadelta T细胞。为展示我们的PBMC-SDKO小鼠平台用于体内评估gammadelta T细胞相关治疗手段,我们使用经辐照的SDKO小鼠和来自9名供者的PBMC进行了gammadelta T细胞植入实验。我们还使用与人淋巴瘤或三阴性乳腺癌细胞系的体外共培养实验,评估了从PBMC植入小鼠中分离的这些gammadelta T细胞的抗癌功能。 方法:经辐照的SDKO小鼠植入来自9名不同人供者的PBMC。在PBMC注射后每周使用流式细胞术监测外周的白细胞植入情况,以计数alphabeta T细胞、gammadelta T细胞及其亚群Vdelta1和Vdelta2的频率和数量。使用抗体偶联磁珠分离植入脾脏和肺部的gammadelta T细胞,然后与Raji或MDA-MB-231细胞体外共培养,以评估其抗肿瘤功能。 结果:我们发现循环gammadelta T细胞在植入的SDKO小鼠中大量扩增。在部分供者中,gammadelta T细胞的浓度高达4×10^2个细胞/μL——这一水平与循环人B细胞(外周血中的一个主要群体)相当。在gammadelta T细胞亚群中,Vdelta2亚群表现出最稳健和一致的扩增,而其他gammadelta T细胞亚群(如Vdelta1)则具有供者依赖性。除外周血外,我们还观察到gammadelta T细胞在植入的SDKO小鼠肺部和脾脏中的稳健植入和回收。我们的体外共培养实验表明,从SDKO小鼠脾脏和肺部分离的gammadelta T细胞显示出CD69细胞表面表达升高、响应癌细胞的granzyme B分泌,并在效靶比为1:1和3:1时减少了Raji或MDA-MB-231细胞数量。我们的结果提示,gammadelta T细胞可从SDKO小鼠中稳健扩增和回收,且回收的细胞对肿瘤细胞具有强效的细胞裂解活性。
查看英文原文 English abstract
Background Gamma delta (gammadelta) T cells represent a minor subset of T lymphocytes capable of recognizing a wide range of universally conserved antigens expressed by cancer cells. Unlike conventional T cells, their recognition is independent of MHC, making them strong candidates for next-generation universal cancer therapeutics targeting various malignancies. Our preliminary donor screening results demonstrated that engrafting human peripheral blood mononuclear cells (PBMCs) into irradiated NSG TM -SGM3-IL-15 × MHC I/II DKO (SDKO) mice could lead to the expansion of circulating gammadelta T cells to a concentration comparable to those in human and robust gammadelta T cell recovery from tissues. To demonstrate our PBMC-SDKO mice platform for in vivo evaluation of gammadelta T cell related therapeutics, we conducted gammadelta T cell engraftment experiments using irradiated SDKO mice and PBMC from 9 donors. We also assessed the anti-cancer functionality of these isolated gammadelta T cells from PBMC engrafted mice using in vitro co-culture experiments with human lymphoma or triple-negative breast cancer cell lines. Methods Irradiated SDKO mice were engrafted with PBMCs from 9 different human donors. Leukocyte engraftment in the periphery was monitored weekly post PBMC injection using flow cytometry to enumerate the frequency and numbers of alphabeta T cells, gammadelta T cells and their subpopulations Vdelta1, and Vdelta2. gammadelta T cells engrafted in spleen and lungs were isolated using antibody conjugated magnetic beads and then co-cultured in vitro with Raji or MDA-MB-231 cells to assess their anti-tumor functionality. Results We found that circulating gammadelta T cells expanded greatly in engrafted SDKO mice. In some of the donors, the concentration of gammadelta T cells reached up to 4×10 2 cells/µL - a level comparable to that of circulating human B cells, which is a major population in peripheral blood. Among the gammadelta T cell subsets, the Vdelta2 subset exhibited the most robust and consistent expansion, while other gammadelta T cell subsets such as the Vdelta1 were donor dependent. In addition to peripheral blood, we also observed robust engraftment and recovery of gammadelta T cells from the lungs and spleens of engrafted SDKO mice. Our in vitro co-culture experiments demonstrated that the gammadelta T cells isolated from the spleens and lungs of SDKO mice showed elevated cell surface expression of CD69, granzyme B secretion in response to cancer cells and reduced the number of Raji or MDA-MB-231 cell numbers at effector to target ratios of 1:1 and 3:1. Our results suggest that gammadelta T cells can be robustly expanded and recovered from the SDKO mice and that the recovered cells possess potent cytolytic activity against tumor cells.
利益披露 Disclosure
K. Tsai, None.. B. Parry, None.. D. Rose, None.. J. G. Keck, None.. L. Yao, None.

← 返回 AACR 2026 检索